Clinical Report: Teaching AI to Read Liquid Biopsies

Overview

A study published in Nature Communications evaluates the potential of large language models (LLMs) to identify diagnostic biomarkers from cell-free RNA (cfRNA) data. LLMs showed variability in performance compared to traditional methods, indicating the necessity for further validation before clinical application.

Background

Liquid biopsies, particularly those analyzing cfRNA, offer a minimally invasive approach to diagnostic biomarker discovery. The complexity of cfRNA datasets presents challenges in identifying clinically useful biomarkers. The integration of artificial intelligence, specifically LLMs, may enhance the biomarker discovery process, but their reliability compared to established methods is not fully established.

Data Highlights

No numerical data provided in the source material.

Key Findings

• LLMs outperformed random gene selections in identifying diagnostic biomarkers from cfRNA data.
• Performance was strongest in the tuberculosis dataset, with some LLM-generated panels comparable to traditional methods.
• Results were more modest in Kawasaki disease and multisystem inflammatory syndrome in children (MIS-C), and weakest in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
• LLMs frequently selected genes associated with immune and inflammatory pathways.
• Inconsistent performance in independent biomarker discovery workflows was noted, not surpassing established machine learning approaches.
• Rigorous validation of LLM-generated biomarker signatures is necessary before clinical application.

Clinical Implications

The findings indicate that LLMs can assist in generating hypotheses for biomarker discovery, but should be used alongside traditional bioinformatics and statistical methods.

Conclusion

The study indicates that LLMs may serve as tools in biomarker discovery, but their clinical application requires further validation.

Related Resources & Content

1. Nature Communications, 2026 -- Teaching AI to Read Liquid Biopsies
2. Frontiers in Oncology — Artificial intelligence–enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications
3. The ASCO Post — AI-Backed Liquid Biopsies Identify Liver Diseases
4. The ASCO Post — AI-Backed Liquid Biopsies Identify Liver Diseases
5. the asco post — AI-Backed Liquid Biopsies Identify Liver Diseases
6. Artificial intelligence–enabled liquid biopsy in cancer: a systematic review and meta-analysis of diagnostic performance and biological implications
7. AI-Backed Liquid Biopsies Identify Liver Diseases
8. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | JCO Oncology Practice
9. Press Releases
10. Role of ctDNA surveillance is uncertain in early breast cancer
11. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening | New England Journal of Medicine
12. NCA - Screening for Colorectal Cancer-Non-Invasive Biomarker Tests (CAG-00440R) - Decision Memo
13. NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening. | Journal of Clinical Oncology
14. https://www.nature.com/articles/s41467-026-74077-x_reference.pdf
15. A multimodal cell-free RNA language model for liquid biopsy applications